Chinese scientists find "**" ovarian cancer new method, won the second prize of national science and technology progress award of 2011

Ovarian cancer is a fatal gynecological malignancy. Medical workers from Zhejiang University, Huazhong University of Science and Technology and Peking University in China have discovered and targeted the characteristics of “immune escape” of ovarian cancer cells, optimized their treatment options, and effectively improved the survival rate of patients with advanced ovarian cancer.

Among the results of the National Science and Technology Awards announced on the 14th, the first completed project of Professor Xie Xing of Zhejiang University and the research and application of the repression mechanism of ovarian cancer were awarded in 2011. National Science and Technology Progress Award second prize.

According to reports, ovarian cancer is known as the "invisible killer" that affects the lives and health of women. Apart from the lack of a very good diagnostic method, it also has an irreversible mechanism of progress. Statistics show that more than three-quarters of patients are late at the initial visit.

Xie said that the study found that ovarian cancer cells are intelligent cells that have the ability to “escape immune”. They can produce various substances that can effectively change the functions of various immune cells of the human body, making immune cells invisible or unable to do so. Attack it. This allows rapid growth and transfer in the body.

Medical workers began to look for ways. They created some monoclonal antibodies autonomously. After using these antibodies, the immune function of the body was effectively improved.

The resistance of ovarian cancer cells is also a problem faced by medical workers. Zhejiang University’s gynecological oncology research team reported for the first time that some molecules could be used as markers for drug sensitivity. On this basis, the research team designed a number of vectors that can effectively inhibit the molecular resistance of ovarian cancer cells, laying the foundation for the next truly clinical application.

At the same time as years of basic research, Zhejiang University’s gynecological oncology team has also established a multi-center, large-sample clinical research base in conjunction with Huazhong University of Science and Technology and Peking University, and has expanded to hospitals in Zhejiang, Hubei and other cities to explore new types of ovaries. Comprehensive treatment of cancer. Xie said that after clinical application, the joint research group has improved the survival rate of ovarian cancer. The 5-year overall survival rate of patients is 48.6% and the late-stage cancer is 36.1%, which is higher than the survival rate data released by the National Center for Health Statistics of the United States in 2010. .

It is understood that some of the research results of the team have been incorporated into the national planning textbooks and the national guidelines for the diagnosis and treatment of gynecological oncology. The relevant results have been applied by more than 20 domestic and foreign companies.

512-slice CT Scanner

512 Slice CT,Heart CT Scanner,CT Scanner Screening,Ge Cardiac CT Scanner

MinFound Medical Systems Co., Ltd , https://www.minfoundmed.com

Posted on